José Luis
Díaz Díaz
Publicaciones (91) Publicaciones de José Luis Díaz Díaz
2024
-
Age- and sex-based heterogeneity in coronary artery plaque presence and burden in familial hypercholesterolemia: A multi-national study
American Journal of Preventive Cardiology, Vol. 17
-
Association of BMI, lipid-lowering medication, and age with prevalence of type 2 diabetes in adults with heterozygous familial hypercholesterolaemia: a worldwide cross-sectional study
The Lancet Diabetes and Endocrinology, Vol. 12, Núm. 11, pp. 811-823
-
Characteristics of Coronary Atherosclerosis Related to Plaque Burden Regression During Treatment With Alirocumab: The ARCHITECT Study
Circulation. Cardiovascular imaging, Vol. 17, Núm. 1, pp. e016206
-
Estándares de la Sociedad Española de Arteriosclerosis 2024 para el control global del riesgo vascular
Clínica e investigación en arteriosclerosis, Vol. 36, Núm. 3, pp. 133-194
-
Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study
The Lancet, Vol. 403, Núm. 10421, pp. 55-66
-
Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study
Atherosclerosis, Vol. 393
-
Long-term sex differences in atherosclerotic cardiovascular disease in individuals with heterozygous familial hypercholesterolaemia in Spain: a study using data from SAFEHEART, a nationwide, multicentre, prospective cohort study
The Lancet Diabetes and Endocrinology, Vol. 12, Núm. 9, pp. 643-652
-
PCSK9 inhibitors on the management of primary and secondary cardiovascular prevention
Lipids in Health and Disease , Vol. 23, Núm. 1
2023
-
Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study
Circulation, Vol. 147, Núm. 19, pp. 1436-1443
-
Control de la hipercolesterolemia en España: una misma situación con diferentes realidades autonómicas
Clínica e investigación en arteriosclerosis, Vol. 35, Núm. 5, pp. 219-225
-
Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study
The Lancet
-
Impact of conducting a genetic study on the management of familial hypercholesterolemia; A retrospective cohort study of 4854 patients from the SEA Dyslipidemia Registry
Journal of Clinical Lipidology, Vol. 17, Núm. 6, pp. 717-731
-
Impact of physician's perception about LDL cholesterol control in clinical practice when treating patients in Spain
Atherosclerosis, Vol. 375, pp. 38-44
-
PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk
International Journal of Molecular Sciences, Vol. 24, Núm. 3
-
Persistence with long-term PCSK9 inhibitor treatment and its effectiveness in familial hypercholesterolaemia: data from the SAFEHEART study
European journal of preventive cardiology, Vol. 30, Núm. 4, pp. 320-328
-
Prevalencia de dislipemia aterogénica, factores relacionados y grado de control lipídico en la población general de Galicia: Estudio GALIPEMIAS
Clínica e investigación en arteriosclerosis, Vol. 35, Núm. 4, pp. 178-184
-
Recomendaciones nutricionales en la prevención y tratamiento de la dislipemia aterogénica: Grupo de Trabajo Dislipemia Aterogénica, Sociedad Española de Arteriosclerosis
Clínica e investigación en arteriosclerosis, Vol. 35, Núm. 3, pp. 155-163
2022
-
A resilient type of familial hypercholesterolaemia: case-control follow-up of genetically characterized older patients in the SAFEHEART cohort
European Journal of Preventive Cardiology, Vol. 29, Núm. 5, pp. 795-801
-
Differences in the diabetogenic effect of statins in patients with prediabetes. The PRELIPID study
Medicina Clinica, Vol. 158, Núm. 11, pp. 531-539
-
Dyslipidemia observatory: Treatment of hypercholesterolemia in Spain, context and levers for improvement in clinical practice
Clinica e Investigacion en Arteriosclerosis, Vol. 34, Núm. 5, pp. 253-260